Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business

# Executive Summary This whitepaper discusses the FDA's Accelerated Approval (AA) pathway, emphasizing its significance and challenges: - **Historical Context**: Established to expedite access to treatments for serious conditions, particularly during the HIV/AIDS crisis. - **Current Landscape**: AA approvals have increased, with notable cases raising public scrutiny over drug efficacy and pricing. - **Challenges Identified**: Issues include low levels of evidence for approvals, lagging confirmatory trials, and public distrust in the system. - **Policy Recommendations**: Suggestions for reform include improving transparency, strengthening oversight, and aligning financial incentives with evidence and value. - **Future Directions**: Ongoing evaluation of the AA pathway is critical for maintaining public trust and ensuring patient access to effective therapies.